In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Halozyme Therapeutics Inc (NASDAQ: HALO) closed the day trading at $68.1 down -4.62% from the previous closing price of $71.4. In other words, the price has decreased by -$4.62 from its previous closing price. On the day, 2.27 million shares were traded. HALO stock price reached its highest trading level at $72.0 during the session, while it also had its lowest trading level at $68.01.
Ratios:
For a better understanding of HALO, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.29. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.59. In the meantime, Its Debt-to-Equity ratio is 3.00 whereas as Long-Term Debt/Eq ratio is at 1.59.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Connaughton Bernadette sold 829 shares for $71.60 per share. The transaction valued at 59,356 led to the insider holds 42,123 shares of the business.
Torley Helen sold 16,569 shares of HALO for $1,141,925 on Dec 01 ’25. The PRESIDENT AND CEO now owns 708,719 shares after completing the transaction at $68.92 per share. On Nov 12 ’25, another insider, Torley Helen, who serves as the PRESIDENT AND CEO of the company, sold 20,000 shares for $70.55 each. As a result, the insider received 1,410,990 and left with 733,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 8008355328 and an Enterprise Value of 8845250560. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.31, and their Forward P/E ratio for the next fiscal year is 8.34. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.44 while its Price-to-Book (P/B) ratio in mrq is 15.88. Its current Enterprise Value per Revenue stands at 7.117 whereas that against EBITDA is 10.876.
Stock Price History:
The Beta on a monthly basis for HALO is 0.95, which has changed by 0.40470302 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $79.50, while it has fallen to a 52-week low of $46.26. The 50-Day Moving Average of the stock is -1.53%, while the 200-Day Moving Average is calculated to be 8.10%.
Shares Statistics:
Over the past 3-months, HALO traded about 2.18M shares per day on average, while over the past 10 days, HALO traded about 2114600 shares per day. A total of 117.52M shares are outstanding, with a floating share count of 116.24M. Insiders hold about 1.16% of the company’s shares, while institutions hold 103.04% stake in the company. Shares short for HALO as of 1763078400 were 12479411 with a Short Ratio of 5.72, compared to 1760486400 on 11510110. Therefore, it implies a Short% of Shares Outstanding of 12479411 and a Short% of Float of 14.78.
Earnings Estimates
. The current assessment of Halozyme Therapeutics Inc (HALO) involves the perspectives of 6.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $1.74, with high estimates of $1.99 and low estimates of $1.53.
Analysts are recommending an EPS of between $6.39 and $5.46 for the fiscal current year, implying an average EPS of $6.14. EPS for the following year is $7.97, with 5.0 analysts recommending between $9.02 and $7.18.
Revenue Estimates
6 analysts predict $398.22M in revenue for. The current quarter. It ranges from a high estimate of $417M to a low estimate of $378M. As of. The current estimate, Halozyme Therapeutics Inc’s year-ago sales were $298.01MFor the next quarter, 6 analysts are estimating revenue of $377.29M. There is a high estimate of $399.07M for the next quarter, whereas the lowest estimate is $357.8M.
A total of 8 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $1.36B, while the lowest revenue estimate was $1.32B, resulting in an average revenue estimate of $1.34B. In the same quarter a year ago, actual revenue was $1.02BBased on 7 analysts’ estimates, the company’s revenue will be $1.68B in the next fiscal year. The high estimate is $1.79B and the low estimate is $1.58B.
